• Get great deals on gift baskets View details
  • We scape the web daily looking for great deals for you!
  • Get Dad a new Weber Grill this Holiday Season Shop now



Stelara (ustekinumab) is an injectable medication used to treat moderately to severely active ulcerative colitis. It is the first anti-IL-12/23 biologic approved by the U.S. Food and Drug Administration for this indication.

Stelara injections have been demonstrated in pivotal clinical trials to provide effective remission and mucosal healing in adults with ulcerative colitis. Patients who responded to an induction dose of Stelara and a maintenance dose had improved health-related quality of life, as well as a decreased need for corticosteroids, compared to those who did not receive Stelara. The maintenance dose of Stelara has also been suggested to help sustain remission, with long-term reports of up to 4.5 years.

Stelara works by targeting two inflammation-promoting proteins - interleukin (IL)-12 and IL-23. It blocks the inflammatory signals they produce, thereby reducing inflammation in the intestine and promoting mucosal healing. This can help to improve symptoms such as abdominal pain and diarrhea, and increase the amount of time spent in remission.

Stelara injections are generally well-tolerated, but as with all medications, they can cause side effects such as upper respiratory tract infection, headache, and injection-site reaction. The most serious potential risks include risks for infection, reactivation of tuberculosis, and hypersensitivity. Close medical monitoring is recommended.

For adults with moderately to severely active ulcerative colitis, Stelara injections may be an effective and safe treatment option. In clinical trials, Stelara resulted in improved quality of life, fewer medications, and sustained remission over long-term use. To ensure safety and maximize the benefits, it is important to follow the instructions of a healthcare provider for proper administration and monitoring.

Check out some of the links above from our sponsors.